Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

July 30, 2020July 30, 2020

Collaboration Seeks to Reduce Prostate Cancer Disparities in African Americans

News

The Prostate Cancer Foundation (PCF) and Robert F. Smith, chairman and CEO of Vista Equity Partners are supporting research on a new non-invasive genetic test to determine a man’s ... Read more

June 19, 2020June 19, 2020

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

News

Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 ... Read more

March 11, 2020March 23, 2020

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

News

Treatment with Corvus Pharmaceuticals‘ ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well tolerated and showed promising anti-tumor activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

News

A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — is able to overcome prostate cancer resistance to ... Read more

November 4, 2019

Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC

News

Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone ... Read more

October 23, 2019

FDA Grants Breakthrough Device Designation to IsoPSA Blood Test for Early Prostate Cancer Diagnosis

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Cleveland Diagnostics’ IsoPSA, a minimally invasive blood test for early detection of prostate cancer. The IsoPSA ... Read more

October 16, 2019October 25, 2019

Long-term Hormone Therapy Does More Harm than Good in Prostate Cancer Patients with Low PSA Levels After Surgery, Analysis Shows

News

Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they ... Read more

September 23, 2019

Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says

News

Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt ... Read more

August 29, 2019

FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says

News

The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment ... Read more

Pin It on Pinterest